Quantum BioPharma Ltd. (NASDAQ: QNTM) closed a non-brokered private placement of 26 Class A multiple voting shares at C$3.11 per share on Nov. 9, generating gross proceeds of C$80.86, according to the company’s announcement of results from its Nov. 10, 2026, annual general and special meeting. The small dollar figure understates the governance significance: the issuance lifted the aggregate voting power of Class A multiple voting shares from approximately 57.01% to 68.22%. Xorax Family Trust, associated with CEO Zeeshan Saeed, and Fortius Research and Trading Corp., controlled by director Anthony Durkacz, each acquired 13 shares. The transaction was completed under shareholder authorization granted in 2025, with proceeds designated for general working capital purposes.
The placement matters because it deepens insider control at a company whose shareholders also approved a series of structural measures with long-term implications. Shareholders elected all five director nominees, reappointed MNP LLP as auditor and authorized the issuance of additional Class A multiple voting shares to maintain up to 70% aggregate voting power. That authorization gives the board room to preserve insider voting dominance even as new equity is issued, a mechanism that can entrench management while limiting the relative influence of common shareholders.
Shareholders further approved a 2026 omnibus equity incentive plan, a potential share consolidation at a ratio of up to 10-for-1 and a potential corporate name change, with the board retaining discretion over implementation. A consolidation can be used to raise a low share price to meet exchange listing requirements or to appeal to institutional investors, but it also reduces the number of outstanding shares without changing the underlying economics. The name change, if executed, could signal a repositioning of the company’s public identity. For investors, the combination of a 68.22% insider voting bloc and discretionary authority over consolidation and rebranding means the board can act with limited practical challenge from minority holders.
Quantum is a biopharmaceutical company developing treatments for neurodegenerative and metabolic disorders and alcohol misuse disorders. Through its wholly owned subsidiary Lucid Psycheceuticals Inc., it is focused on Lucid-MS, a patented new chemical entity shown in preclinical models to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis. It also invented UNBUZZD and spun out the OTC version to Unbuzzd Wellness Inc., retaining a 19.84% ownership stake as of March 31, 2026, plus royalties of 7% of sales until payments total $250 million, dropping to 3% thereafter in perpetuity, and 100% of rights to develop similar products for pharmaceutical and medical uses. The full press release is available at https://ibn.fm/UagXR, and the latest news and updates relating to Quantum BioPharma (NASDAQ: QNTM) are available in the company’s newsroom at https://ibn.fm/QNTM.
The announcement was distributed through BioMedWire, one of 75+ brands within the Dynamic Brand Portfolio at IBN, which provides wire solutions via InvestorWire and editorial syndication to 5,000+ outlets. A related BioMedNewsBreak covering Lantern Pharma’s Phase 1a glioblastoma data and its advance toward a Phase 1b/2a trial is available here.


